$CELU

Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Celularity Announces Naveen Jain to Join Board of Directors Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBENEWSWIRE) — Celularity Inc. (

Celularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 23, 2026, Celularity Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers party thereto (collectively, the “Purchasers”),

Celularity Inc. (CELU) raised over $10 million in initial financing, part of a $28 million recapitalization plan. The funds will support commercial execution and manufacturing. The company aims for positive cash flow by Q1 2027, reduced monthly cash burn, and increased revenue. CELU stock is up 13.04% to $1.30.

Celularity Inc (CELU) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 11, 2026, Celularity Inc. (“Celularity”) received written notifications from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that Celularity has regained compliance with the minimum bid price requirement

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

Celularity (CELU) partners with MuseCell Innovations to manufacture Dezawa MuseCells in the U.S. The deal could generate $300M in purchases over five years. Celularity's stock is up 64.70% to $1.48.

Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.

Celularity Inc. (CELU) received a Nasdaq notice for late quarterly filings, failing to submit reports for Q1 and Q2 2026. The company has until September 4 to submit a compliance plan. Trading continues on Nasdaq under 'CELU'. Celularity is working to file the reports promptly.

Celularity Inc (CELU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, Celularity Inc. (the “Company”) terminated the employment of Rick Gonzalez, the Company’s Chief Commerc

Celularity Inc (CELU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 LOAN agreement This Loan Agreement, dated as of June 29, 2026 (“ Agreement ”), is among Celularity Inc., a Delaware corporation (the “ Borrower ”), and Philip & Daniele Barach Family Trust (the “ Lender ” and, together with the Borrower,